After years of neglect, glial cells are finally registering on drug developers'radar. Evidence has accrued over the last seven years that glia are activated by opioids (e.g. morphine, methadone, meperidine, and oxycodone) and that this opioid-induced glial response suppresses opioid analgesia, resulting in the development of opioid tolerance and dependence. A literature has developed linking opiate efficacy and side effects to their influence on glial cells within the central nervous system (CNS) via the signaling pathway mediated by toll-like receptor 4 (TLR4). In a recent report, the Yin lab has provided the first direct evidence that morphine creates its neuroinflammatory effects by binding to the TLR4 accessory protein, MD-2, and inducing TLR4/MD-2 dimerization and subsequent TLR4 signaling activation in a similar fashion to the classical TLR4 ligand, lipopolysaccharide (LPS;endotoxin). Further, morphine induces neuroinflammation solely through its binding in a specific LPS-binding pocket of MD-2, indicating that disruption of the essential TLR4/MD-2 interactions is sufficient to suppress morphine-induced neuroinflammation. The overall objective of the current proposal is to validate the TLR4/MD-2 complex as a feasible target to suppress morphine-induced neuroinflammation by exogenous chemical probes. Our central hypothesis is that by blocking the formation of the TLR4/MD-2 complex, opioid-induced inflammatory response can also be suppressed and thereby enhance morphine analgesia. The proposed research is significant because it is expected to validate the TLR4/MD-2 complex as a novel target for improving the analgesic efficacy of opioids. The proposed research is innovative because it is the first drug discovery approach attempting to regulate opioid-induced glial activation while almost all previous research focused on neurons. The studies are built on a strong collaborative team with expertise that optimizes its chance to effectively bridge the atomic details of TLR4 activation with the macroscopic pain management inefficiencies of opioid use.
Aim 1 and Aim 2 are two independent, parallel approaches that aim to attain highly specific inhibitors of the TLR4/MD-2 interactions.
We aim to develop previously identified MD-2 peptides and T5342126 derivatives as potent, selective inhibitors of the TLR4/MD-2 complex with desired PK/PD properties.
Aim 3 will test the working hypothesis that by disrupting the TLR4/MD- 2 complex, opioid-induced neuroinflammation can also be blocked, thus enhancing acute opioid analgesia. The optimized inhibitors from Aims 1 and 2 will be tested in vitro using various cell lines, in ex vivo microglia, as well as in animal models. The proposed studies, if successful, are projected to yield significant novel outcome: First, the results will further the understanding of the mechanism of clinically relevant opioid-induced neuroinflammation. Second, the TLR4/MD-2 complex will be validated as a feasible target for developing neuroinflammation suppressant. Third, the stapled peptide and small-molecule antagonists of the TLR4 pathway identified from the proposed research will serve as prototypes for potential drug candidates.

Public Health Relevance

The proposed research aims to validate novel drug targets by using peptide and small-molecule inhibitors of the critical TLR4/MD-2 complex that regulates important inflammatory response. Multidisciplinary technologies will be employed to select, design, and evaluate new chemical probes predicted to suppress neuroinflammation, thereby rendering an innovative strategy to optimize the current pain management therapy.

National Institute of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
Research Project (R01)
Project #
Application #
Study Section
Cellular and Molecular Biology of Glia Study Section (CMBG)
Program Officer
Fabian, Miles
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Colorado at Boulder
Schools of Arts and Sciences
United States
Zip Code
Zhang, Shuting; Hu, Zhenyi; Tanji, Hiromi et al. (2018) Small-molecule inhibition of TLR8 through stabilization of its resting state. Nat Chem Biol 14:58-64
Grace, Peter M; Wang, Xiaohui; Strand, Keith A et al. (2018) DREADDed microglia in pain: Implications for spinal inflammatory signaling in male rats. Exp Neurol 304:125-131
Smith, Christina E; Soti, Subada; Jones, Torey A et al. (2017) Non-steroidal Anti-inflammatory Drugs Are Caspase Inhibitors. Cell Chem Biol 24:281-292
Zhang, Lei; Dewan, Varun; Yin, Hang (2017) Discovery of Small Molecules as Multi-Toll-like Receptor Agonists with Proinflammatory and Anticancer Activities. J Med Chem 60:5029-5044
Das, Nabanita; Dewan, Varun; Grace, Peter M et al. (2016) HMGB1 Activates Proinflammatory Signaling via TLR5 Leading to Allodynia. Cell Rep 17:1128-1140
Bajo, M; Montgomery, S E; Cates, L N et al. (2016) Evaluation of TLR4 Inhibitor, T5342126, in Modulation of Ethanol-Drinking Behavior in Alcohol-Dependent Mice. Alcohol Alcohol 51:541-8
Ning, Peng; Jiang, Jiacheng; Li, Longchun et al. (2016) A mitochondria-targeted ratiometric two-photon fluorescent probe for biological zinc ions detection. Biosens Bioelectron 77:921-7
Wang, X; Zhang, Y; Peng, Y et al. (2016) Pharmacological characterization of the opioid inactive isomers (+)-naltrexone and (+)-naloxone as antagonists of toll-like receptor 4. Br J Pharmacol 173:856-69
Li, Jing; Csakai, Adam; Jin, Jialin et al. (2016) Therapeutic Developments Targeting Toll-like Receptor-4-Mediated Neuroinflammation. ChemMedChem 11:154-65
Grace, Peter M; Strand, Keith A; Galer, Erika L et al. (2016) Morphine paradoxically prolongs neuropathic pain in rats by amplifying spinal NLRP3 inflammasome activation. Proc Natl Acad Sci U S A 113:E3441-50

Showing the most recent 10 out of 34 publications